Efficacy of Ethnodyne Visio in Parkinson's Disease

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02815800

Acronym

ETHNOPARK

Enrollment

Registered

2016-06-28

Start date

2016-09-02

Completion date

2018-03-12

Last updated

2018-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson's Disease

Keywords

Treatment, Motor signs, Non motor signs, Fluctuations, Open labelled

Brief summary

ETHNODYNE VISIO is a food supplement composed of an innovative plant-based active ingredient acting alongside vitamin B2. It is proposed in patients with visual problems. Based on clinical and experimental data, the investigators propose a pilot open study in order to test the efficacy of Ethnodyne visio in patients with Parkinson 's disease (PD). The hypothesis is that Ethnodyne visio may improve motor and non motor signs of PD. 24 patients with PD will be evaluated before and after 3 months of add on treatment by Ethnodyne visio.

Interventions

DIETARY_SUPPLEMENTETHNODYNE VISIO

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

OTHER

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

40 Years to 75 Years

Healthy volunteers

Inclusion criteria

* Patients with Parkinson disease (PD) with at least 3 years of evolution * Hoehn and Yahr score 2 or 3 * with moderate fluctuations (score 1 or 2 for item 3 score IV MSD UPDRS) * with no modification in anti-parkinsonian drugs since at least 1 month * minimental test \>24

Exclusion criteria

* known intolerance to Ethnodyne visio * woman of childbearing potential or breastfeeding * anticipated anti-parkinsonian treatment modification during the 3 months of the study * antidepressant or anxiolytic drugs modified within one month prior to inclusion visit * other chronic disease * concomitant participation in a another clinical trial * Subject under legal guardianship

Design outcomes

Primary

Measure	Time frame
Change in MDS UPDRS III score	baseline and following 3 months of treatment

Secondary

Measure	Time frame
Change in MDS UPDRS I, II and IV score	baseline and following 3 months of treatment
Change in Levodopa equivalent dose treatment (equivalence table)	baseline and following 3 months of treatment
Frequency, seriousness and severity of adverse event reactions	during the 3 months of treatment

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026